Background: Hemorrhagic transformation (HT) is common among acute ischemic stroke patients after treatment with intravenous thrombolysis (IVT). We analyzed potential relationships between markers of cerebral small vessel disease (CSVD) and HT in patients after IVT.
Methods: This study retrospectively analyzed computed tomography (CT) data for acute ischemic stroke patients before and after treatment with recombinant tissue plasminogen activator at a large Chinese hospital between July 2014 and June 2021. Total CSVD score were summed by individual CSVD markers including leukoaraiosis, brain atrophy and lacune. Binary regression analysis was used to explore whether CSVD markers were related to HT as the primary outcome or to symptomatic intracranial hemorrhage (sICH) as a secondary outcome.
Results: A total of 397 AIS patients treated with IVT were screened for inclusion in this study. Patients with missing laboratory data ( = 37) and patients treated with endovascular therapy ( = 42) were excluded. Of the 318 patients included, 54 (17.0%) developed HT within 24-36 h of IVT, and 14 (4.3%) developed sICH. HT risk was independently associated with severe brain atrophy (OR 3.14, 95%CI 1.43-6.92, = 0.004) and severe leukoaraiosis (OR 2.41, 95%CI 1.05-5.50, = 0.036), but not to severe lacune level (OR 0.58, 95%CI 0.23-1.45, = 0.250). Patients with a total CSVD burden ≥1 were at higher risk of HT (OR 2.87, 95%CI 1.38-5.94, = 0.005). However, occurrence of sICH was not predicted by CSVD markers or total CSVD burden.
Conclusion: In patients with acute ischemic stroke, severe leukoaraiosis, brain atrophy and total CSVD burden may be risk factors for HT after IVT. These findings may help improve efforts to mitigate or even prevent HT in vulnerable patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106596 | PMC |
http://dx.doi.org/10.3389/fneur.2023.1144564 | DOI Listing |
BMC Geriatr
January 2025
Department of Pharmacy, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi Nishitokyo-Shi, Tokyo, 202-8585, Japan.
Background: Edaravone is marketed in nine countries, although only Japan has approved edaravone for improvement of neurological symptom, disability of activities of daily living (ADL), and functional disability associated with acute stroke. This study aimed to elucidate the association of edaravone use with ADL using real-world data of older patients with atherothrombotic stroke.
Methods: This retrospective observational research using the Medical Data Vision database in Japan included patients aged 65 years and older who had acute ischemic stroke of the atherothrombotic subtype.
J Cardiothorac Vasc Anesth
December 2024
Kore University, Enna, Italy and Centro Cuore GB Morgagni, Catania, Italy.
Objectives: The benefit of combining multiple mechanical circulatory support (MCS) systems in patients with cardiogenic shock (CS) is debated. This review examines patient characteristics across studies to identify differences and assesses if patients with a higher-risk clinical profile receive Impella unloading.
Design: A systematic review and meta-analysis was conducted to examine if there were significant differences in baseline clinical parameters among patients receiving MCS in addition to venoarterial extracorporeal membrane oxygenation (VA ECMO).
Br J Sports Med
January 2025
Vascular Surgery, Asan Medical Center, Songpa-gu, Seoul, Korea (the Republic of)
Objectives: Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with recent acute coronary syndrome (ACS) raises concerns owing to potential risk of recurrent ACS or fatal arrhythmias. This study investigated the association between longitudinal PA changes following an ACS diagnosis and subsequent cardiovascular outcomes, including non-fatal coronary events, non-fatal stroke and cardiovascular mortality.
View Article and Find Full Text PDFMol Immunol
January 2025
Department of Urology, Renmin Hospital of Wuhan University. Wuhan, Hubei Province, PR China. Electronic address:
Background: Renal ischemia-reperfusion injury (IRI) is a prevailing manifestation of acute kidney injury (AKI) with limited treatment options. TRIM44 has emerged as a possible target for treatment due to its regulatory function in inflammatory pathways.
Methods: In vivo and in vitro models were employed to ascertain the TRIM44 impact on renal IRI.
Clin Neurol Neurosurg
January 2025
Department of Medicine, Federal University of Piauí, Teresina, Brazil.
Introduction: Intravenous tirofiban (IT) is shown to be potentially effective in acute ischemic stroke (AIS) patients submitted to mechanical thrombectomy, despite its safety and efficacy are not well established. However, there is a lack of evidence on the effects of IT on endovascular thrombectomy (EVT) in patients with AIS due to large artery atherosclerosis (LAA).
Objectives: To assess the safety and efficacy of IT in AIS patients due to LAA submitted to EVT.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!